Recent News

• 02.06.2026 - Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
• 01.30.2026 - Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
• 01.29.2026 - Lexicon Announces Proposed Public Offering of Common Stock
• 01.23.2026 - Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
• 01.21.2026 - Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
• 01.12.2026 - Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
• 01.09.2026 - Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
• 01.07.2026 - Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 12.10.2025 - Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Recent Filings

• 02.06.2026 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.02.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.02.2026 - EX-99.1 EX-99.1
• 02.02.2026 - 8-K Current report
• 01.30.2026 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 01.30.2026 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 01.29.2026 - EX-99.1 EX-99.1
• 01.29.2026 - 8-K Current report